Highlights
Recent News
Ocugen Names Interim CMO as $130M Convertible Fuels Gene Therapy Push Toward FDA Filings
Ocugen has parted ways with its chief medical officer just as the biotech enters a pivotal stretch for its lead...
Uranium Energy Eyes Two Key Catalysts Over the Next Two Months as Stock Tests Support
Uranium Energy Corp. finds itself caught between a punishing short-term sell-off and a stack of structural catalysts that could shift...
Sparc AI’s Dual Push into Ukraine and Tampa Puts Navigation Software to the Test
Electronic warfare and GPS-jamming have become a persistent battlefield reality, and a small Canadian software firm is betting its technology...
BioNTech’s $650 Million R&D Quarter: Shareholders Back Board Expansion as Market Awaits Lung Cancer Data
Despite sitting on nearly $20 billion in cash, BioNTech is burning through money at an accelerating pace as it races...
Popular
Net Worth
Ocugen’s Gene Therapy Candidates Race Toward FDA Filings, But the Market Isn’t Ready to Celebrate
Ocugen is making quiet but meaningful progress across its pipeline of gene therapy programmes, yet the stock...
Marvell’s Optical Ambition and Insider Moves Create a Tale of Two Narratives
Marvell Technology is walking a tightrope between a towering long-term growth story and near-term market pressures that...
Intel’s Shareholder Mandate and Apple’s Limited Foundry Role: A Tale of Two Realities
Intel’s annual general meeting on May 13 delivered a resounding endorsement of leadership, but the market had...
Rolls-Royce Grounds a Hydrogen Milestone as Geopolitical Headwinds Rattle Aviation Sentiment
Rolls-Royce has delivered a genuine technological breakthrough—successfully running a Pearl-15 engine on 100% hydrogen at full takeoff...